Radiopharm Theranostics (RADX), a clinical-stage biopharmaceutical company specializing in oncology radiopharmaceuticals, has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event is scheduled for May 14, 2025, in New York City. The company's management team will be available for one-on-one meetings with interested parties, who can arrange meetings by contacting John Perez at jperez@dboralcapital.com. Radiopharm focuses on developing innovative treatments for areas with high unmet medical needs in oncology.
Radiopharm Theranostics (RADX), un'azienda biofarmaceutica in fase clinica specializzata in radiofarmaci oncologici, ha annunciato la sua partecipazione al prossimo D. Boral Capital Inaugural Global Conference. L'evento si terrà il 14 maggio 2025 a New York City. Il team di gestione dell'azienda sarà disponibile per incontri individuali con le parti interessate, che possono fissare appuntamenti contattando John Perez all'indirizzo jperez@dboralcapital.com. Radiopharm si concentra sullo sviluppo di trattamenti innovativi per aree con elevate esigenze mediche insoddisfatte in oncologia.
Radiopharm Theranostics (RADX), una empresa biofarmacéutica en etapa clínica especializada en radiofármacos oncológicos, ha anunciado su participación en la próxima D. Boral Capital Inaugural Global Conference. El evento está programado para el 14 de mayo de 2025 en la ciudad de Nueva York. El equipo directivo de la empresa estará disponible para reuniones individuales con las partes interesadas, quienes pueden concertar citas contactando a John Perez en jperez@dboralcapital.com. Radiopharm se enfoca en desarrollar tratamientos innovadores para áreas con altas necesidades médicas no satisfechas en oncología.
Radiopharm Theranostics(RADX)는 종양학 방사성의약품을 전문으로 하는 임상 단계의 바이오제약 회사로, 다가오는 D. Boral Capital Inaugural Global Conference에 참여할 것임을 발표했습니다. 이 행사는 2025년 5월 14일 뉴욕시에서 개최됩니다. 회사 경영진은 관심 있는 분들과 일대일 미팅을 진행할 예정이며, 미팅 예약은 jperez@dboralcapital.com의 John Perez에게 연락하면 됩니다. Radiopharm은 종양학에서 의료 수요가 충족되지 않은 분야를 위한 혁신적인 치료법 개발에 주력하고 있습니다.
Radiopharm Theranostics (RADX), une société biopharmaceutique en phase clinique spécialisée dans les radiopharmaceutiques oncologiques, a annoncé sa participation à la prochaine D. Boral Capital Inaugural Global Conference. L'événement est prévu pour le 14 mai 2025 à New York. L'équipe de direction de la société sera disponible pour des réunions individuelles avec les parties intéressées, qui peuvent organiser des rendez-vous en contactant John Perez à jperez@dboralcapital.com. Radiopharm se concentre sur le développement de traitements innovants dans des domaines présentant des besoins médicaux non satisfaits en oncologie.
Radiopharm Theranostics (RADX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf onkologische Radiopharmazeutika spezialisiert hat, hat seine Teilnahme an der bevorstehenden D. Boral Capital Inaugural Global Conference angekündigt. Die Veranstaltung findet am 14. Mai 2025 in New York City statt. Das Management-Team des Unternehmens steht für Einzelgespräche mit Interessenten zur Verfügung, die Termine über John Perez unter jperez@dboralcapital.com vereinbaren können. Radiopharm konzentriert sich auf die Entwicklung innovativer Behandlungen für Bereiche mit hohem ungedecktem medizinischem Bedarf in der Onkologie.
Positive
None.
Negative
None.
SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that members of management will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.
To register for one-on-one meetings with management in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Investors: Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: rc@radiopharmtheranostics.com
Anne Marie Fields Precision AQ (formerly Stern IR) E: annemarie.fields@precisionaq.com
When is Radiopharm Theranostics (RADX) participating in the D. Boral Capital Conference?
Radiopharm Theranostics will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.
How can investors meet with Radiopharm Theranostics management at the D. Boral Capital Conference?
Interested parties can arrange one-on-one meetings with management by contacting John Perez at jperez@dboralcapital.com.
What is Radiopharm Theranostics (RADX) main business focus?
Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need.
Which stock exchanges is Radiopharm Theranostics listed on?
Radiopharm Theranostics is listed on both the Australian Securities Exchange (ASX:RAD) and the Nasdaq (RADX).
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
